Cost-effectiveness analysis of gemcitabine plus cisplatin versus fluorouracil plus cisplatin for first-line treatment of recurrent or metastatic nasopharyngeal carcinoma.

Xudong Chen,Weiting Liang,Ning Wan,Li Zhang,Yunpeng Yang,Jie Jiang,Tiantian Zhang

Oral Oncology（2019）

引用 19|浏览11

暂无评分

摘要

•It is the first economic evaluation for recurrent or metastatic NPC.•GP regimen was extremely cost-effectiveness with an ICER of $7,386 per QALY.•GP regimen was likely recommended as the primarily first treatment option for recurrent or metastatic NPC.

查看译文

关键词

Cost-effectiveness,Recurrent or metastatic,Nasopharyngeal carcinoma,Gemcitabine,Cisplatin,Fluorouracil

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要